References
- Collén A, Bergenhem N, Carlsson L, et al. VEGFA mRNA for regenerative treatment of heart failure. Nat Rev Drug Discov. 2022 Jan;21(1):79-80. doi: 10.1038/s41573-021-00355-6
- Xu J, Tsanakopoulou M, Magnani CJ, et al. A prebiotically plausible synthesis of pyrimidine β-ribonucleosides and their phosphate derivatives involving photoanomerization. Nat Chem. 2017 Apr;9(4):303-309. doi: 10.1038/nchem.2664
- Kavita K, Breaker RR. Discovering riboswitches: the past and the future. Trends Biochem Sci. 2022 Sep 20;S0968-0004(22)00234-1. doi: 10.1016/j.tibs.2022.08.009
- Ozata DM, Gainetdinov I, Zoch A, O’Carroll D, Zamore PD. PIWI-interacting RNAs: small RNAs with big functions. Nat Rev Genet. 2019 Feb;20(2):89-108. doi: 10.1038/s41576-018-0073-3
- Kuo CC, Hänzelmann S, Sentürk Cetin N, et al. Detection of RNA-DNA binding sites in long noncoding RNAs. Nucleic Acids Res. 2019 Apr 8;47(6):
e32 . doi: 10.1093/nar/gkz037 - Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625-38. doi: 10.3109/07853890.2015.1068949
- Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153
- Obici L, Berk JL, González-Duarte A, et al. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2020 Sep;27(3):153-162. doi: 10.1080/13506129.2020.1730790
- Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med. 2017 Apr 13;376(15):1430-1440. doi: 10.1056/NEJMoa1615758
- Wright RS, Ray KK, Real FJ, et al. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021 Mar 9;77(9):1182-1193. doi: 10.1016/j.jacc.2020.12.058
- Wierzbicki AS, Viljoen A. Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia. Expert Opin Biol Ther. 2016 Sep;16(9):1125-34. doi: 10.1080/14712598.2016.1196182
- HoustonMethodist.org [Internet]. Houston, TX: Houston Methodist; c2022. Center for RNA Therapeutics; 2022 [cited 2022 Oct 21]. Available from:
www.houstonmethodist.org/rna-t - FDA.gov [Internet]. Silver Spring, MD: US Food and Drug Administration; c2022. FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine; 2020 Dec 11 [cited 2022 Oct 24]. Available from:
https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19 - CEPI.net [Internet]. Washington, DC: CEPI; c2022. 100 days mission; 2022 [cited 2022 Oct 24]. Available from:
https://100days.cepi.net/ - Terada Y, Kawachi K, Matsuura Y, Kamitani W. MERS coronavirus nsp1 participates in an efficient propagation through a specific interaction with viral RNA. Virology. 2017 Nov;511:95-105. doi: 10.1016/j.virol.2017.08.026
- Shehata MM, Kandeil A, Mostafa A, et al. A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice. Pathogens. 2019 Dec 2;8(4):281. doi: 10.3390/pathogens8040281
- Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005 Aug;23(2):165-75. doi: 10.1016/j.immuni.2005.06.008
- Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9. doi: 10.1073/pnas.1209367109
- Stewart DJ, Kutryk MJB, Fitchett D, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther. 2009 Jun;17(6):1109-15. doi: 10.1038/mt.2009.70
- Stewart DJ, Hilton JD, Arnold JMO, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006 Nov;13(21):1503-11. doi: 10.1038/sj.gt.3302802
- Zangi L, Lui KO, von Gise A, et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol. 2013 Oct;31(10):898-907. doi: 10.1038/nbt.2682
- Gan LM, Lagerström-Fermér M, Carlsson LG, et al. Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nat Commun. 2019 Feb 20;10(1):871. doi: 10.1038/s41467-019-08852-4
- Anttila V, Saraste A, Knuuti J, et al. Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial. Mol Ther Methods Clin Dev. 2020 Jun 1;18:464-472. doi: 10.1016/j.omtm.2020.05.030
- Liu S, Tang L, Zhao X, et al. Yap Promotes Noncanonical Wnt Signals From Cardiomyocytes for Heart Regeneration. Circ Res. 2021 Oct;129(8):782-797. doi: 10.1161/CIRCRESAHA.121.318966
- Kapoor N, Liang W, Marbán E, Cho HC. Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18. Nat Biotechnol. 2013 Jan;31(1):54-62. doi: 10.1038/nbt.2465
- Bai Y, Kan S, Zhou S, et al. Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA. Cell Discov. 2015 Dec 8;1:15040. doi: 10.1038/celldisc.2015.40
- Li Y, Zhou G, Bruno IG, et al. Transient introduction of human telomerase mRNA improves hallmarks of progeria cells. Aging Cell. 2019 Aug;18(4):
e12979 . doi: 10.1111/acel.12979 - Mojiri A, Walther BK, Jiang C, et al. Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice. Eur Heart J. 2021 Nov 7;42(42):4352-4369. doi: 10.1093/eurheartj/ehab547
- Dzul-Huchim VM, Ramirez-Sierra MJ, Martinez-Vega PP, et al. Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by Trypanosoma cruzi in chronically-infected BALB/c mice. PLoS Negl Trop Dis. 2022 Sep 12;16(9):
e0010258 . doi: 10.1371/journal.pntd.0010258 - Kim SC, Stice JP, Chen L, et al. Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ Res. 2009 Dec 4;105(12):1186-95. doi: 10.1161/CIRCRESAHA.109.209643
- Youker KA, Shen H, Bhimaraj A, Torre-Amione G. Abstract 11435: A New Paradigm in Therapy: A Vaccine Against the Progression of Heart Failure. Circulation. 2021 Nov;144(Suppl 1):A11435. doi: 10.1161/circ.144.suppl_1.11435
- Vogel AB, Lambert L, Kinnear E, et al. Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses. Mol Ther. 2018 Feb 7;26(2):446-455. doi: 10.1016/j.ymthe.2017.11.017
- Beissert T, Perkovic M, Vogel A, et al. A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity. Mol Ther. 2020 Jan 8;28(1):119-128. doi: 10.1016/j.ymthe.2019.09.009
- Lu D, Chatterjee S, Xiao K, et al. A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity. Eur Heart J. 2022 Jun 27;
ehac337 . doi: 10.1093/eurheartj/ehac337 - Boada C, Zinger A, Tsao C, et al. Rapamycin-Loaded Biomimetic Nanoparticles Reverse Vascular Inflammation. Circ Res. 2020 Jan 3;126(1):25-37. doi: 10.1161/CIRCRESAHA.119.315185
- Rurik JG, Epstein JA. Uniting Disciplines to Develop Therapeutics: Targeted mRNA Lipid Nanoparticles Reprogram the Immune System In Vivo to Treat Heart Disease. DNA Cell Biol. 2022 Jun;41(6):539-543. doi: 10.1089/dna.2022.0171
DOI: https://doi.org/10.14797/mdcvj.1169 | Journal eISSN: 1947-6108
Language: English
Page range: 64 - 73
Submitted on: Oct 11, 2022
Accepted on: Oct 19, 2022
Published on: Dec 6, 2022
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2022 John P. Cooke, Keith A. Youker, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.